Krystal (KRYS) Q2 Profit Jumps 143%
Krystal Biotech (NASDAQ:KRYS), a gene therapy company specialized in rare skin and genetic diseases, reported its latest quarterly results on August 4, 2025, for the second quarter of fiscal 2025. The company posted better-than-expected financials, reporting GAAP earnings per share of $1.29 compared to the analyst estimate of $1.18 in Q2 2025, and GAAP revenue of $96.0 million against the $91.97 million consensus in Q2 2025. This represents strong double-digit year-over-year growth in both revenue and GAAP earnings per share. The period also saw major international milestones, as its lead gene therapy, VYJUVEK, secured regulatory approvals in Europe and Japan. Overall, the quarter marked robust financial results, progress in global expansion, and a pivotal moment as the U.S. commercial opportunity begins to level off.
Source: Analyst estimates for the quarter provided by FactSet.
Krystal Biotech specializes in developing genetic medicines to treat rare and serious skin and systemic conditions. Its core technology is built around an engineered herpes simplex virus type 1 (HSV-1) platform that allows targeted gene delivery to specific tissues with repeated dosing. This approach enables correction of underlying genetic defects across several disease areas.
Source Fool.com
